1. terryk096
2. faklan25
3. binaryvolt
4. louisianabluesma
5. laszman000
1.binaryvolt 11/01/2018
MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting
2.faklan25 05/03/2018
MorphoSys AG Reports First Quarter 2018 Results
3.faklan25 04/23/2018
MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and Exercise of the Underwriters' Option to Purchase Additional ADSs, Leading to Total Gross Proceeds of USD 239 million
4.faklan25 06/15/2018
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018
5.terryk096 04/26/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in South Korea
6.terryk096 10/25/2018
MorphoSys's Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
7.terryk096 06/13/2018
New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW